POMALIDOMIDE | POMALYST | POMACEL-2MG-4MG

1. POMALIDOMIDE | POMALYST | POMACEL-2MG/4MG POMACEL-2MG/4MG DESCRIPTION : Pomacel 2mg/4mg is a Glenmark Pharmaceuticals product which is endorsed by FDA, containing an active anti-cancer drug called Pomalidomide. Pomacel 2mg/4mg is available as orally bioavailable thalidomide derivative with various therapeutic activities such as; Immuno modulatory Anti-angiogenesis Anti-neoplastic Pomacel 2mg/4mg is like thalidomide & Lenalidomide with related to decreased rate of serum aminotransferase elevations during treatment. This may lead to severe liver injury.Pomacel 2mg/4mg is involved in the treatment for regression & unmanageable multiple myeloma.Pomacel 2mg/4mg is used in the patients who are failing to response for Lenalidomide treatment.Pomacel 2mg/4mg is used in combination with dexamethasone. INDICATION The major therapeutic indication of Pomacel 2mg/4mg is involved in the treatment of multiple myeloma. This treatment is occurred by combining with dexamethasone for reducing the side effect associated with Pomacel 2mgomide.Pomacel

2. 2mg/4mg is majorly indicated in patients who are not reacts for prior two therapies like Lenalidomide & proteasome inhibitor. POMALIDOMIDE | POMALYST | POMACEL-2MG/4MG DOSAGE & ADMINISTRATION The prescribed dose of Pomacelin multiple myeloma is 4mg should be administered orally as once a day on day 1 to 21 of reciprocated 28-day cycles.Pomacel 2mg/4mg should be concomitant with dexamethasone.Pomacel 2mg/4mg Capsules should be taken with or without food. During hematological toxicities: Neutropenia; ANC (absolute neutrophils count) <500/mcl: Postpone the Pomaceltherapy and provide CBC weekly ANC more than or equal to 500/mcl: Continue the Pomacel3mg daily. Thrombocytopenia: Platelets count <25,000/mcL: postpone the Pomaceltreatment &

3. follow the CBC >50,000/mcL: continue 3mg of PomacelPomacel 2mg/4mgwith potent CYP1A2 inhibitor: During this combination reduce the dose of Pomacelby 50% In renal impairment: Initial dose of Pomacel is 3mg In hepatic impairment: Mild to moderate condition, an initial dose of Pomacelis 3mg; in severe condition, the initial dose of Pomacel is 2mg. DRUG INTERACTION Pomalidomide metabolism is mediated by CYP1A2 & CYP3A4. The concomitant use of Pomacel 2mg/4mg with CYP1A2 drugs like Fluvoxamine causes elevation of Cmax& AUC of Pomalidomide and concludes as increased concentration of Pomacelleads to higher extent of adverse effects associated with Pomalid In this condition, reduce the dose of Pomacel 2mg/4mg and recommended. CONTRAINDICATION Pomacel 2mg/4mg should be contraindicated to pregnancy & lactating women. The pregnancy category of Pomacel 2mg/4mg is X. SIDE EFFECTS More common effects of Pomacel 2mg/4mg : If taken during pregnancy, Severe life-threatening human birth defects

4. Fatigue Weakness Low white blood cell count Anemia Constipation Nausea Diarrhea Shortness of breath Upper respiratory infections Back pain Fever. Less common effects of Pomacel 2mg/4mg Neuropathy Dizziness Confusion. CONTACTS Phone : +91- 9987711567 Email: applepharmaceutical@gmail.com WEBSITE: https://myapplepharma.com/pomalidomide.php https://myapplepharma.com/pomacel-2mg.php https://myapplepharma.com/pomacel-4mg.php